Pharmacology Quiz: Estrogen Progestin Risks
20 questions · exam conditions
0:00
Estrogen Progestin RisksQuestion 1 of 20

A 66-year-old woman with osteoporosis is prescribed raloxifene. She has an intact uterus and a history of a deep vein thrombosis 20 years ago. How does the risk profile of raloxifene regarding VTE and endometrial cancer compare to that of unopposed estrogen therapy?

Both carry a similar, increased risk of VTE; however, raloxifene does not increase endometrial cancer risk.
Both carry a similar, increased risk of VTE and a similar, increased risk of endometrial cancer.
Raloxifene has no VTE risk but increases endometrial cancer risk, whereas estrogen increases both.
Raloxifene reduces both VTE risk and endometrial cancer risk compared to estrogen therapy.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Estrogen Progestin Risks

Practice Estrogen Progestin Risks in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Estrogen Progestin Risks, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 66-year-old woman with osteoporosis is prescribed raloxifene. She has an intact uterus and a history of a deep vein thrombosis 20 years ago. How does the risk profile of raloxifene regarding VTE and endometrial cancer compare to that of unopposed estrogen therapy?

  1. Both carry a similar, increased risk of VTE; however, raloxifene does not increase endometrial cancer risk. (correct answer)
  2. Both carry a similar, increased risk of VTE and a similar, increased risk of endometrial cancer.
  3. Raloxifene has no VTE risk but increases endometrial cancer risk, whereas estrogen increases both.
  4. Raloxifene reduces both VTE risk and endometrial cancer risk compared to estrogen therapy.
Explanation: Raloxifene is a selective estrogen receptor modulator (SERM). It acts as an estrogen agonist in bone (preventing osteoporosis) but as an estrogen antagonist in the endometrium and breast. Therefore, unlike unopposed estrogen, it does not cause endometrial proliferation and does not increase endometrial cancer risk. However, like estrogen, it alters hepatic synthesis of clotting factors and carries a 2- to 3-fold increased risk of venous thromboembolism.

Question 2

A 62-year-old woman stops combined menopausal hormone therapy (MHT) after 10 years of use. Based on data from large clinical trials, what is the most likely trajectory for her elevated MHT-associated risks of VTE and breast cancer after cessation?

  1. The elevated risks for both VTE and breast cancer decline gradually and simultaneously, returning to baseline after about 5 years.
  2. The elevated risks for both VTE and breast cancer are permanent and will not return to the baseline for non-users.
  3. The elevated breast cancer risk returns to baseline within one year, but the VTE risk remains elevated indefinitely.
  4. The elevated VTE risk declines rapidly to baseline within months, while the elevated breast cancer risk persists for several years. (correct answer)
Explanation: When evaluating post-cessation risks after hormone therapy, you need to understand that different adverse effects have distinct pathophysiological mechanisms that determine how quickly risks normalize after stopping treatment. The correct answer is D because VTE and breast cancer risks follow very different trajectories after MHT cessation. VTE risk from hormone therapy is primarily due to acute prothrombotic effects—increased clotting factors and decreased fibrinolysis. Once you stop MHT, these hemostatic changes reverse quickly as hormone levels drop, returning VTE risk to baseline within months. In contrast, breast cancer risk elevation persists because hormones promote growth of existing malignant or pre-malignant cells that have already been initiated during treatment. Even after stopping hormones, these cellular changes don't immediately disappear, maintaining elevated cancer risk for several years. Option A incorrectly suggests both risks decline simultaneously over 5 years—this ignores the different mechanisms involved. Option B is wrong because neither risk is permanent; both eventually return to baseline, just on different timelines. Option C reverses the actual pattern, incorrectly stating that breast cancer risk normalizes quickly while VTE risk persists indefinitely. For pharmacology exams, remember that drug-related adverse effects resolve at different rates based on their underlying mechanisms. Acute physiological effects (like hormone-induced clotting changes) typically reverse quickly after drug cessation, while effects involving cellular transformation or structural changes (like cancer promotion) often persist longer even after the drug is stopped.

Question 3

A 58-year-old postmenopausal woman with a history of a single, provoked deep vein thrombosis (DVT) following orthopedic surgery 10 years prior is discussing menopausal hormone therapy (MHT) for severe vasomotor symptoms. The increased risk of recurrent venous thromboembolism (VTE) with combined oral estrogen-progestin therapy is primarily mediated by which of the following physiological changes?

  1. Estrogen-induced increase in hepatic synthesis of procoagulant factors II, VII, X, and fibrinogen. (correct answer)
  2. Progestin-mediated platelet hyperaggregation and increased thromboxane A2 synthesis.
  3. Estrogen-induced peripheral vasodilation leading to venous stasis in the lower extremities.
  4. Progestin-induced downregulation of endothelial tissue plasminogen activator (t-PA) expression.
Explanation: Oral estrogen undergoes first-pass metabolism in the liver, which significantly increases the hepatic synthesis of various coagulation factors (Factors II, VII, X, and fibrinogen) and decreases levels of natural anticoagulants like antithrombin and Protein S. This shifts the hemostatic balance towards a prothrombotic state, representing the primary mechanism for increased VTE risk. Progestins have a much smaller effect on coagulation, and while estrogen does cause vasodilation, it is not the primary driver of VTE risk. Downregulation of t-PA is not the principal mechanism.

Question 4

A 59-year-old woman taking combined continuous estrogen-progestin therapy for 5 years is diagnosed with an estrogen receptor-positive (ER+) invasive ductal carcinoma of the breast. Which statement accurately reflects the likely influence of her hormone therapy on the characteristics of her cancer?

  1. The cancer is more likely to be of a higher grade and less differentiated compared to cancers in non-users.
  2. The therapy likely caused the cancer to be ER-negative, as high estrogen levels downregulate the receptor.
  3. The cancer is more likely to be detected at a later stage due to increased breast density masking mammographic findings. (correct answer)
  4. The therapy is associated with a better prognosis and lower mortality once breast cancer is diagnosed.
Explanation: Estrogen-progestin therapy increases mammographic breast density, which can make it more difficult to detect tumors on mammograms. This can lead to a delay in diagnosis, with cancers being found at a more advanced stage or larger size. While the therapy increases the risk of developing ER+ cancer, it does not typically make the tumors higher grade (they are often well-differentiated). Importantly, despite later detection, some studies have suggested prognosis is not necessarily worse, but the masking effect is a well-established risk.

Question 5

A clinician is explaining the risks of a combined oral contraceptive containing drospirenone and ethinyl estradiol to a 24-year-old patient. Which statement best differentiates the impact of this medication on the risk of venous versus arterial thrombotic events?

  1. The relative risk for venous thromboembolism (VTE) is increased several-fold, while the risk for arterial events is only minimally increased in healthy non-smokers. (correct answer)
  2. The risks for both VTE and arterial events are increased to the same degree due to a shared mechanism of estrogen-induced hypercoagulability.
  3. The risk for arterial events like stroke is substantially higher than the VTE risk due to progestin-induced effects on blood pressure and lipids.
  4. There is a significant increase in VTE risk, but the medication is protective against arterial events by promoting vasodilation and favorable lipid changes.
Explanation: The use of combined hormonal contraceptives is associated with a well-established 3- to 5-fold increase in the relative risk of VTE. The effect on arterial thrombosis (myocardial infarction, ischemic stroke) is much smaller, with the risk being only slightly elevated, particularly in young, healthy women without other risk factors like smoking, hypertension, or migraines. The mechanisms are also different, with VTE risk being driven by changes in hepatic clotting factors and arterial risk being more related to blood pressure, lipids, and direct vascular effects.

Question 6

A 55-year-old woman with a prior hysterectomy for benign leiomyomas has severe, persistent hot flashes. Her medical history includes well-controlled hypertension and a family history of a mother diagnosed with breast cancer at age 72. Which statement accurately reflects the risks associated with initiating estrogen-only therapy in this patient?

  1. Estrogen-only therapy carries a high risk of ovarian cancer that outweighs the benefits for her vasomotor symptoms.
  2. Combined estrogen-progestin therapy is necessary to offset the breast cancer risk from her family history.
  3. All forms of hormone therapy are absolutely contraindicated due to her history of hypertension and family history of cancer.
  4. The primary risk is VTE; the late-onset family history of breast cancer is not a strong contraindication, and progestin is not indicated. (correct answer)
Explanation: When evaluating hormone replacement therapy (HRT), you need to assess individual risk factors and understand when progestin is necessary. The key distinction is that progestin is only required to prevent endometrial hyperplasia in women with an intact uterus. This patient had a hysterectomy, so estrogen-only therapy is appropriate and actually preferred over combination therapy. Her primary risk with estrogen therapy is venous thromboembolism (VTE), especially given her age. However, her family history of breast cancer at age 72 represents a late-onset case with minimal genetic implications for her own risk - early-onset breast cancer (typically before age 50) or multiple affected relatives would be more concerning. Answer D correctly identifies VTE as the primary concern while recognizing that late-onset family history isn't a strong contraindication and progestin isn't needed post-hysterectomy. Answer A is wrong because estrogen-only therapy doesn't significantly increase ovarian cancer risk, and this wouldn't be the primary concern anyway. Answer B incorrectly suggests adding progestin for breast cancer protection - progestin actually increases breast cancer risk and is unnecessary after hysterectomy. Answer C is too absolute; well-controlled hypertension and late-onset family history of breast cancer are relative, not absolute, contraindications. For pharmacology exams, remember that HRT decisions hinge on uterine status: estrogen-only for post-hysterectomy patients, combination therapy for those with intact uteri. Always weigh individual risk factors rather than applying blanket contraindications, and distinguish between early and late-onset family cancer histories.

Question 7

The 'timing hypothesis' of menopausal hormone therapy (MHT) posits that initiating MHT closer to the onset of menopause may confer cardiovascular benefits, whereas starting many years later may be harmful. The increased risk of coronary events when initiating combined MHT in a 69-year-old, 18 years past menopause, is thought to be related to estrogen's effect on:

  1. pre-existing, unstable atherosclerotic plaques, potentially promoting their rupture. (correct answer)
  2. the progressive decline in renal clearance of progestins, leading to cardiotoxic levels.
  3. a heightened sensitivity of the older myocardium to progestin-induced vasospasm.
  4. the induction of de novo atherosclerosis in previously healthy coronary arteries.
Explanation: The timing hypothesis suggests that in younger, recently postmenopausal women, estrogen may have beneficial vascular effects, such as improving endothelial function and preventing plaque formation. In older women who likely have established, complex atherosclerotic plaques, the pro-inflammatory and prothrombotic effects of oral estrogen may destabilize these plaques, leading to an increased risk of rupture and subsequent myocardial infarction or stroke. Estrogen is not thought to cause de novo atherosclerosis in this context.

Question 8

The addition of a progestin to estrogen replacement therapy is critical for preventing endometrial cancer in women with a uterus. The primary molecular mechanism for this protection involves progestin-induced:

  1. conversion of estradiol to the less potent estrone within endometrial cells, reducing estrogenic stimulation.
  2. downregulation of estrogen receptors and induction of enzymes that promote differentiation and limit proliferation. (correct answer)
  3. competitive antagonism at the estrogen receptor, physically blocking estradiol from binding in the endometrium.
  4. stimulation of the local uterine immune system to identify and destroy hyperplastic endometrial cells.
Explanation: Progestins protect the endometrium by directly opposing the proliferative effects of estrogen. Upon binding to the progesterone receptor, they initiate a signaling cascade that has several effects: it reduces the number of estrogen receptors on endometrial cells (downregulation), it induces the expression of enzymes (like 17β-hydroxysteroid dehydrogenase) that convert potent estradiol to weaker estrone, and it promotes cellular differentiation into a secretory state rather than a proliferative one. This combination effectively halts and reverses the estrogen-driven growth that can lead to hyperplasia and cancer.

Question 9

A 61-year-old woman with an intact uterus requires menopausal hormone therapy. She has a history of hypertriglyceridemia. Her provider chooses a transdermal estrogen patch and a separate oral micronized progesterone. What is the principal pharmacological advantage of using transdermal estrogen over an oral formulation in this specific patient?

  1. Transdermal delivery avoids first-pass hepatic metabolism, mitigating adverse effects on clotting factor synthesis and lipid profiles. (correct answer)
  2. Transdermal patches provide more consistent serum estrogen levels, which has been shown to eliminate the risk of endometrial hyperplasia.
  3. The transdermal route selectively delivers estrogen to bone and vaginal tissue, minimizing systemic exposure and thrombotic risk.
  4. Oral estrogen is poorly absorbed in patients with lipid abnormalities, leading to subtherapeutic levels for symptom control.
Explanation: The primary advantage of the transdermal route for estrogen delivery is the avoidance of the first-pass effect in the liver. Oral estrogens are extensively metabolized by the liver, leading to a disproportionately large impact on the synthesis of clotting factors, SHBG, and triglycerides. By bypassing the liver, transdermal estrogen provides effective systemic levels for symptom control while having a much smaller impact on these hepatic markers, resulting in a lower risk of VTE and less exacerbation of hypertriglyceridemia.

Question 10

A study reports that the baseline incidence of VTE in healthy women of reproductive age is 2 per 10,000 woman-years. For users of a second-generation combined oral contraceptive, the relative risk is 4.0. What is the attributable risk of VTE due to the use of this contraceptive?

  1. 2 additional cases per 10,000 woman-years.
  2. 4 additional cases per 10,000 woman-years.
  3. 6 additional cases per 10,000 woman-years. (correct answer)
  4. 8 additional cases per 10,000 woman-years.
Explanation: This question requires a two-step calculation. First, calculate the absolute risk in users: Baseline Risk × Relative Risk = 2/10,000 × 4.0 = 8/10,000 woman-years. Second, calculate the attributable risk (also known as risk difference), which is the absolute risk in the exposed group minus the absolute risk in the unexposed (baseline) group: Attributable Risk = 8/10,000 - 2/10,000 = 6 additional cases per 10,000 woman-years. This represents the number of cases directly attributable to the medication.

Question 11

A 44-year-old woman requests a prescription for a combined oral contraceptive (COC). Her medical history is significant for migraines with aura and she smokes 20 cigarettes per day. Her blood pressure is 130/85 mmHg and her BMI is 28 kg/m². Which factor presents the most significant absolute contraindication to prescribing a COC due to an unacceptably high risk of arterial thrombosis (stroke)?

  1. Age over 35 years combined with smoking ≥15 cigarettes per day.
  2. History of migraine with aura, regardless of age or smoking status. (correct answer)
  3. Body mass index (BMI) in the overweight category.
  4. Systolic blood pressure in the high-normal range.
Explanation: While age >35 and heavy smoking is a major contraindication due to synergistic risk of VTE and MI, a history of migraine with aura is considered an independent and absolute contraindication for combined hormonal contraceptives. This is due to a substantially increased risk of ischemic stroke, which is a type of arterial thrombosis. The other factors are relative contraindications or risk factors that add to the risk profile, but migraine with aura is a standalone reason to avoid estrogen-containing contraceptives.

Question 12

A 53-year-old woman with an intact uterus initiates estrogen-only therapy for debilitating menopausal symptoms. Her physician failed to add a progestin. This therapeutic regimen places her at a significantly increased risk for endometrial adenocarcinoma primarily because unopposed estrogen:

  1. directly causes mutagenic DNA damage in endometrial stromal cells, leading to neoplastic initiation.
  2. induces continuous, unopposed proliferation of the endometrium, leading to simple, complex, or atypical hyperplasia. (correct answer)
  3. downregulates immune surveillance within the uterus, allowing pre-cancerous cells to evade apoptosis.
  4. promotes angiogenesis within the myometrium, providing a rich blood supply for nascent tumors.
Explanation: The primary risk of unopposed estrogen in a woman with a uterus is endometrial cancer. The mechanism involves estrogen's potent mitogenic effect on the endometrium. Without the differentiating and anti-proliferative effects of a progestin, the endometrium undergoes continuous proliferation, which can progress from simple to atypical hyperplasia, a well-established precursor to endometrial adenocarcinoma. Estrogen is considered a tumor promoter in this context, not a direct mutagen (initiator). While it may have effects on immunity and angiogenesis, the core mechanism is uncontrolled proliferation and hyperplasia.

Question 13

A 44-year-old woman requests a prescription for a combined oral contraceptive (COC). Her medical history is significant for migraines with aura and she smokes 20 cigarettes per day. Her blood pressure is 130/85 mmHg and her BMI is 28 kg/m². Which factor presents the most significant absolute contraindication to prescribing a COC due to an unacceptably high risk of arterial thrombosis (stroke)?

  1. Age over 35 years combined with smoking ≥15 cigarettes per day.
  2. History of migraine with aura, regardless of age or smoking status. (correct answer)
  3. Body mass index (BMI) in the overweight category.
  4. Systolic blood pressure in the high-normal range.
Explanation: While age >35 and heavy smoking is a major contraindication due to synergistic risk of VTE and MI, a history of migraine with aura is considered an independent and absolute contraindication for combined hormonal contraceptives. This is due to a substantially increased risk of ischemic stroke, which is a type of arterial thrombosis. The other factors are relative contraindications or risk factors that add to the risk profile, but migraine with aura is a standalone reason to avoid estrogen-containing contraceptives.

Question 14

A 61-year-old woman with an intact uterus requires menopausal hormone therapy. She has a history of hypertriglyceridemia. Her provider chooses a transdermal estrogen patch and a separate oral micronized progesterone. What is the principal pharmacological advantage of using transdermal estrogen over an oral formulation in this specific patient?

  1. Transdermal delivery avoids first-pass hepatic metabolism, mitigating adverse effects on clotting factor synthesis and lipid profiles. (correct answer)
  2. Transdermal patches provide more consistent serum estrogen levels, which has been shown to eliminate the risk of endometrial hyperplasia.
  3. The transdermal route selectively delivers estrogen to bone and vaginal tissue, minimizing systemic exposure and thrombotic risk.
  4. Oral estrogen is poorly absorbed in patients with lipid abnormalities, leading to subtherapeutic levels for symptom control.
Explanation: The primary advantage of the transdermal route for estrogen delivery is the avoidance of the first-pass effect in the liver. Oral estrogens are extensively metabolized by the liver, leading to a disproportionately large impact on the synthesis of clotting factors, SHBG, and triglycerides. By bypassing the liver, transdermal estrogen provides effective systemic levels for symptom control while having a much smaller impact on these hepatic markers, resulting in a lower risk of VTE and less exacerbation of hypertriglyceridemia.

Question 15

A 66-year-old woman with osteoporosis is prescribed raloxifene. She has an intact uterus and a history of a deep vein thrombosis 20 years ago. How does the risk profile of raloxifene regarding VTE and endometrial cancer compare to that of unopposed estrogen therapy?

  1. Both carry a similar, increased risk of VTE; however, raloxifene does not increase endometrial cancer risk. (correct answer)
  2. Both carry a similar, increased risk of VTE and a similar, increased risk of endometrial cancer.
  3. Raloxifene has no VTE risk but increases endometrial cancer risk, whereas estrogen increases both.
  4. Raloxifene reduces both VTE risk and endometrial cancer risk compared to estrogen therapy.
Explanation: Raloxifene is a selective estrogen receptor modulator (SERM). It acts as an estrogen agonist in bone (preventing osteoporosis) but as an estrogen antagonist in the endometrium and breast. Therefore, unlike unopposed estrogen, it does not cause endometrial proliferation and does not increase endometrial cancer risk. However, like estrogen, it alters hepatic synthesis of clotting factors and carries a 2- to 3-fold increased risk of venous thromboembolism.

Question 16

Observational studies have suggested a potentially higher risk of venous thromboembolism (VTE) with combined oral contraceptives (COCs) containing third-generation progestins (e.g., desogestrel) or drospirenone compared to those with second-generation progestins (e.g., levonorgestrel). What is the proposed mechanism for this difference?

  1. Drospirenone and desogestrel directly activate platelets to a greater extent than levonorgestrel.
  2. Drospirenone and desogestrel are more potent inducers of hepatic cytochrome P450 enzymes, increasing estrogen metabolism.
  3. Second-generation progestins cause less fluid retention, which reduces venous stasis and lowers VTE risk.
  4. Second-generation progestins have greater androgenic activity, which partially counteracts estrogen's procoagulant effects. (correct answer)
Explanation: When evaluating VTE risk with different oral contraceptives, you need to understand how various hormonal components interact with the coagulation system. The key insight is that estrogen has inherent procoagulant effects, and different progestins can either enhance or counteract these effects based on their androgenic properties. The correct answer is D because second-generation progestins like levonorgestrel possess significant androgenic activity. This androgenic effect partially opposes estrogen's procoagulant actions, including its tendency to increase clotting factors and reduce anticoagulant proteins. Third-generation progestins (desogestrel) and drospirenone were specifically developed to have reduced androgenic activity, making them more "estrogen-friendly" but potentially allowing estrogen's procoagulant effects to predominate. Option A is incorrect because the mechanism isn't primarily about direct platelet activation differences between progestins. Option B misrepresents the relationship—increased estrogen metabolism would actually decrease, not increase, VTE risk, and these progestins aren't notably different P450 inducers. Option C incorrectly focuses on fluid retention as the primary mechanism, when the issue is fundamentally about coagulation balance rather than venous stasis from fluid changes. Remember this principle: newer isn't always safer in pharmacology. Third-generation progestins were designed to reduce androgenic side effects like acne and hirsutism, but this "improvement" may have inadvertently increased VTE risk by removing the protective androgenic opposition to estrogen's coagulant effects. Always consider the trade-offs when comparing drug generations.

Question 17

A 62-year-old woman stops combined menopausal hormone therapy (MHT) after 10 years of use. Based on data from large clinical trials, what is the most likely trajectory for her elevated MHT-associated risks of VTE and breast cancer after cessation?

  1. The elevated risks for both VTE and breast cancer decline gradually and simultaneously, returning to baseline after about 5 years.
  2. The elevated risks for both VTE and breast cancer are permanent and will not return to the baseline for non-users.
  3. The elevated breast cancer risk returns to baseline within one year, but the VTE risk remains elevated indefinitely.
  4. The elevated VTE risk declines rapidly to baseline within months, while the elevated breast cancer risk persists for several years. (correct answer)
Explanation: When evaluating post-cessation risks after hormone therapy, you need to understand that different adverse effects have distinct pathophysiological mechanisms that determine how quickly risks normalize after stopping treatment. The correct answer is D because VTE and breast cancer risks follow very different trajectories after MHT cessation. VTE risk from hormone therapy is primarily due to acute prothrombotic effects—increased clotting factors and decreased fibrinolysis. Once you stop MHT, these hemostatic changes reverse quickly as hormone levels drop, returning VTE risk to baseline within months. In contrast, breast cancer risk elevation persists because hormones promote growth of existing malignant or pre-malignant cells that have already been initiated during treatment. Even after stopping hormones, these cellular changes don't immediately disappear, maintaining elevated cancer risk for several years. Option A incorrectly suggests both risks decline simultaneously over 5 years—this ignores the different mechanisms involved. Option B is wrong because neither risk is permanent; both eventually return to baseline, just on different timelines. Option C reverses the actual pattern, incorrectly stating that breast cancer risk normalizes quickly while VTE risk persists indefinitely. For pharmacology exams, remember that drug-related adverse effects resolve at different rates based on their underlying mechanisms. Acute physiological effects (like hormone-induced clotting changes) typically reverse quickly after drug cessation, while effects involving cellular transformation or structural changes (like cancer promotion) often persist longer even after the drug is stopped.

Question 18

A 59-year-old woman taking combined continuous estrogen-progestin therapy for 5 years is diagnosed with an estrogen receptor-positive (ER+) invasive ductal carcinoma of the breast. Which statement accurately reflects the likely influence of her hormone therapy on the characteristics of her cancer?

  1. The cancer is more likely to be of a higher grade and less differentiated compared to cancers in non-users.
  2. The therapy likely caused the cancer to be ER-negative, as high estrogen levels downregulate the receptor.
  3. The cancer is more likely to be detected at a later stage due to increased breast density masking mammographic findings. (correct answer)
  4. The therapy is associated with a better prognosis and lower mortality once breast cancer is diagnosed.
Explanation: Estrogen-progestin therapy increases mammographic breast density, which can make it more difficult to detect tumors on mammograms. This can lead to a delay in diagnosis, with cancers being found at a more advanced stage or larger size. While the therapy increases the risk of developing ER+ cancer, it does not typically make the tumors higher grade (they are often well-differentiated). Importantly, despite later detection, some studies have suggested prognosis is not necessarily worse, but the masking effect is a well-established risk.

Question 19

A 55-year-old woman with a prior hysterectomy for benign leiomyomas has severe, persistent hot flashes. Her medical history includes well-controlled hypertension and a family history of a mother diagnosed with breast cancer at age 72. Which statement accurately reflects the risks associated with initiating estrogen-only therapy in this patient?

  1. Estrogen-only therapy carries a high risk of ovarian cancer that outweighs the benefits for her vasomotor symptoms.
  2. Combined estrogen-progestin therapy is necessary to offset the breast cancer risk from her family history.
  3. All forms of hormone therapy are absolutely contraindicated due to her history of hypertension and family history of cancer.
  4. The primary risk is VTE; the late-onset family history of breast cancer is not a strong contraindication, and progestin is not indicated. (correct answer)
Explanation: When evaluating hormone replacement therapy (HRT), you need to assess individual risk factors and understand when progestin is necessary. The key distinction is that progestin is only required to prevent endometrial hyperplasia in women with an intact uterus. This patient had a hysterectomy, so estrogen-only therapy is appropriate and actually preferred over combination therapy. Her primary risk with estrogen therapy is venous thromboembolism (VTE), especially given her age. However, her family history of breast cancer at age 72 represents a late-onset case with minimal genetic implications for her own risk - early-onset breast cancer (typically before age 50) or multiple affected relatives would be more concerning. Answer D correctly identifies VTE as the primary concern while recognizing that late-onset family history isn't a strong contraindication and progestin isn't needed post-hysterectomy. Answer A is wrong because estrogen-only therapy doesn't significantly increase ovarian cancer risk, and this wouldn't be the primary concern anyway. Answer B incorrectly suggests adding progestin for breast cancer protection - progestin actually increases breast cancer risk and is unnecessary after hysterectomy. Answer C is too absolute; well-controlled hypertension and late-onset family history of breast cancer are relative, not absolute, contraindications. For pharmacology exams, remember that HRT decisions hinge on uterine status: estrogen-only for post-hysterectomy patients, combination therapy for those with intact uteri. Always weigh individual risk factors rather than applying blanket contraindications, and distinguish between early and late-onset family cancer histories.

Question 20

The Women's Health Initiative (WHI) trial demonstrated an increased risk of invasive breast cancer in women taking combined estrogen-progestin therapy, but not in women with a prior hysterectomy taking estrogen-only therapy. Which statement best explains the differential impact of the progestin component on breast tissue in this context?

  1. Progestin converts conjugated equine estrogens into more potent metabolites that have a higher affinity for breast tissue receptors.
  2. Progestin increases the mitotic activity and proliferation of breast epithelial cells, acting as a promoter for latent malignant cells. (correct answer)
  3. Progestin antagonizes the normally protective, anti-proliferative effects that estrogen exerts on breast glandular tissue.
  4. The medroxyprogesterone acetate used in the study is a weak carcinogen that directly initiates malignant transformation in breast cells.
Explanation: Current evidence suggests that the addition of a progestin to estrogen therapy increases breast cancer risk by promoting cell proliferation. Both estrogen and progesterone receptors are present in breast tissue, and their stimulation leads to increased mitotic activity. Progestin appears to amplify this effect, promoting the growth of existing, clinically occult cancers rather than acting as a direct initiator of new cancers. Estrogen is not considered protective in breast tissue, and progestins are not known to be direct carcinogens or to alter estrogen metabolism in this way.